CN102008431A - 一种莫西沙星双层栓及其制备方法 - Google Patents
一种莫西沙星双层栓及其制备方法 Download PDFInfo
- Publication number
- CN102008431A CN102008431A CN2010105483062A CN201010548306A CN102008431A CN 102008431 A CN102008431 A CN 102008431A CN 2010105483062 A CN2010105483062 A CN 2010105483062A CN 201010548306 A CN201010548306 A CN 201010548306A CN 102008431 A CN102008431 A CN 102008431A
- Authority
- CN
- China
- Prior art keywords
- suppository
- moxifloxacin
- double
- release
- substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003702 moxifloxacin Drugs 0.000 title claims abstract description 42
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 title claims abstract description 42
- 239000000829 suppository Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 210000001215 vagina Anatomy 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 20
- 238000013268 sustained release Methods 0.000 claims abstract description 8
- 239000012730 sustained-release form Substances 0.000 claims abstract description 8
- 239000008280 blood Substances 0.000 claims abstract description 4
- 210000004369 blood Anatomy 0.000 claims abstract description 4
- 239000000758 substrate Substances 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 claims description 12
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 claims description 12
- 238000002844 melting Methods 0.000 claims description 10
- 230000008901 benefit Effects 0.000 claims description 9
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 9
- 230000008018 melting Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 238000013019 agitation Methods 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000006216 vaginal suppository Substances 0.000 claims description 6
- 229940120293 vaginal suppository Drugs 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims description 4
- 239000001828 Gelatine Substances 0.000 claims description 2
- 241000405070 Percophidae Species 0.000 claims description 2
- 239000012943 hotmelt Substances 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 206010046914 Vaginal infection Diseases 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 6
- 238000002347 injection Methods 0.000 abstract description 6
- 238000007910 systemic administration Methods 0.000 abstract description 6
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 5
- 201000008100 Vaginitis Diseases 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 241000606161 Chlamydia Species 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 229940126701 oral medication Drugs 0.000 abstract description 3
- 238000010579 first pass effect Methods 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000606153 Chlamydia trachomatis Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940038705 chlamydia trachomatis Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 206010028470 Mycoplasma infections Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011437 continuous method Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940020367 moxifloxacin injection Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229930185107 quinolinone Natural products 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105483062A CN102008431B (zh) | 2010-11-18 | 2010-11-18 | 一种莫西沙星双层栓及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105483062A CN102008431B (zh) | 2010-11-18 | 2010-11-18 | 一种莫西沙星双层栓及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102008431A true CN102008431A (zh) | 2011-04-13 |
CN102008431B CN102008431B (zh) | 2012-07-04 |
Family
ID=43838907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010105483062A Withdrawn - After Issue CN102008431B (zh) | 2010-11-18 | 2010-11-18 | 一种莫西沙星双层栓及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102008431B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102652752A (zh) * | 2012-04-26 | 2012-09-05 | 吉林大学珠海学院 | 一种治疗老年性阴道炎的药物组合物及其制备方法 |
CN107617051A (zh) * | 2017-09-28 | 2018-01-23 | 张洪林 | 一种用于痔疮治疗的药物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1729978A (zh) * | 2005-08-30 | 2006-02-08 | 吴祥根 | 注射用莫西沙星或其盐的冻干粉针剂及其制备方法 |
-
2010
- 2010-11-18 CN CN2010105483062A patent/CN102008431B/zh not_active Withdrawn - After Issue
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1729978A (zh) * | 2005-08-30 | 2006-02-08 | 吴祥根 | 注射用莫西沙星或其盐的冻干粉针剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
《数理医药学杂志》 20070615 张志伟等 盐酸莫西沙星栓的制备及质量控制 366-367 1-7 第20卷, 第3期 2 * |
《河北医药》 20060326 杨劼等 异烟肼双层栓的研制及药动学 226-227 1-7 第28卷, 第3期 2 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102652752A (zh) * | 2012-04-26 | 2012-09-05 | 吉林大学珠海学院 | 一种治疗老年性阴道炎的药物组合物及其制备方法 |
CN107617051A (zh) * | 2017-09-28 | 2018-01-23 | 张洪林 | 一种用于痔疮治疗的药物 |
Also Published As
Publication number | Publication date |
---|---|
CN102008431B (zh) | 2012-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101002912A (zh) | 用于治疗痛经的月舒滴丸制备方法 | |
CN103462883A (zh) | 一种苦参碱二元醇质体温敏凝胶剂及其制备方法 | |
CN102008431B (zh) | 一种莫西沙星双层栓及其制备方法 | |
CN102302505B (zh) | 治疗盆腔炎的药物组合物及其应用 | |
CN103520085A (zh) | 克霉唑或其盐膨胀栓及制备方法 | |
CN102283800B (zh) | 一种治疗阴道炎的硝酸舍他康唑栓剂及其制备方法 | |
US20110091536A1 (en) | Compositions comprising euphorbia prostrata and process of preparation thereof | |
EA021943B1 (ru) | Способ изготовления вагинального суппозитория | |
CN104707040B (zh) | 柏糜消阴道栓及其制备方法 | |
WO2018161890A1 (zh) | 小檗碱在制备治疗急性软组织损伤的药物中的应用 | |
CN104887642A (zh) | 一种盐酸林可霉素阴道泡腾片及制备方法 | |
CN100592912C (zh) | 一种治疗妇科疾病的外用复方制剂及其制备方法 | |
CN101181283B (zh) | 一种抗痔疮药物组合物 | |
CN101756991B (zh) | 盐酸阿夫唑嗪的缓释滴丸 | |
CN102000074A (zh) | 四氢小檗红碱制备用于治疗精神分裂症用途的药物 | |
CN102125559A (zh) | 一种含有己酮可可碱和卡络磺钠的药物组合物及其用途 | |
CN101940585A (zh) | 一种以荭草素-2"-O-β-L-半乳糖苷为主要成分的组合物及其用途 | |
CN102100683B (zh) | 一种缓溶性外用避孕膜 | |
CN104147291B (zh) | 一种妇科盆腔炎肛门栓及其制备方法 | |
CA2897038C (en) | Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof | |
Miao et al. | Analysis of dosage form of traditional Chinese medicine | |
CN106420907A (zh) | 一种苦豆子生物碱双层栓剂及其制备方法 | |
CN101327233B (zh) | 一种用于治疗淋病和非淋的复方外用制剂 | |
CN117860653A (zh) | 一种治疗妇科炎症的阴道栓剂 | |
CN110279766A (zh) | 一种复方黄连药剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Zhao Xinlu Document name: Notification of Passing Examination on Formalities |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200102 Address after: 100124 1605, floor 13, building 3, No. 82, East Fourth Ring Middle Road, Chaoyang District, Beijing Patentee after: Beijing Huayao Kechuang Pharmaceutical Technology Development Co.,Ltd. Address before: 110179 Liaoning province Shenyang Hunnan New Long Street No. 10-1 Co-patentee before: Guan Yi Patentee before: Shenyang Yiling Pharmaceutical Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
AV01 | Patent right actively abandoned |
Granted publication date: 20120704 Effective date of abandoning: 20230720 |
|
AV01 | Patent right actively abandoned |
Granted publication date: 20120704 Effective date of abandoning: 20230720 |
|
AV01 | Patent right actively abandoned | ||
AV01 | Patent right actively abandoned |